Lymphoma Trial, Recruiting NCT06067347 Sponsor: Massachusetts General Hospital Condition: Lymphoma
Back to Lymphoma

Lymphoma Trial, Recruiting

NCT06067347
Recruiting Not Applicable 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed (confirmed by a tissue sample/biopsy) with a type of blood cancer involving mature T-cells or NK-cells that has either never been treated, has come back after treatment, or has stopped responding to treatment.
  • Most subtypes of a group of cancers called peripheral T-cell lymphoma (PTCL) are eligible — if you are unsure whether your specific subtype qualifies, confirm with the trial site.

Who may not be able to join:

  • People diagnosed with certain specific types of T-cell or NK-cell cancers, including: T-cell large granular lymphocytic leukemia, skin-based T-cell lymphomas such as mycosis fungoides (including transformed versions), Sézary syndrome, primary cutaneous CD30+ disorders, or early/precursor forms of T/NK-cell cancers.
  • Adults who are not able to give their own consent to participate.
  • People who are under 18 years of age, including infants, children, and teenagers.
  • Women who are currently pregnant.
  • People who are currently imprisoned.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 650-224-0183

Australian sites

Royal Adelaide Hospital, Adelaide, South Australia
+61 8 7074 0000
Peter MacCallum Cancer Centre, Melbourne, Victoria
+03-8559-5000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
5 January 2024
Est. completion
1 January 2028

Where this trial is recruiting

🇦🇺 Australia 🇯🇵 Japan 🇿🇦 South Africa 🇺🇸 United States

2 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Overall Survival; Progression-free Survival; Duration of Response; Time to progression; Number of subjects proceeding to stem cell transplantation; Association of tumor specific somatic variants with treatment response

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov